TCBPY (TC BioPharm (Holdings)) LT-Debt-to-Total-Asset: 0.14 (As of Dec. 2024)


What is TC BioPharm (Holdings) LT-Debt-to-Total-Asset?

TC BioPharm (Holdings) TCBPY LT-Debt-to-Total-Asset is 0.14 as of Dec. 2024.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TC BioPharm (Holdings)'s long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.14.

TC BioPharm (Holdings)'s long-term debt to total assets ratio declined from Dec. 2023 (0.17) to Dec. 2024 (0.14). It may suggest that TC BioPharm (Holdings) is progressively becoming less dependent on debt to grow their business.

TC BioPharm (Holdings)  (OTCPK:TCBPY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TC BioPharm (Holdings) LT-Debt-to-Total-Asset Related Terms

TC BioPharm (Holdings) LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) LT-Debt-to-Total-Asset Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.36 0.27 0.16 0.17 0.14

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.20 0.17 0.20 0.14

TC BioPharm (Holdings) LT-Debt-to-Total-Asset Calculation

TC BioPharm (Holdings)'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=1.48/10.53
=

TC BioPharm (Holdings)'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=1.48/10.53
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.14 mean?
TC BioPharm (Holdings) (TCBPY) has a LT-Debt-to-Total-Asset of 0.14 as of Dec. 2024. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s LT-Debt-to-Total-Asset too high?
TC BioPharm (Holdings)'s current LT-Debt-to-Total-Asset is 0.14.
How does TC BioPharm (Holdings)'s LT-Debt-to-Total-Asset compare to SIGY and CNBX?
TC BioPharm (Holdings)'s LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current LT-Debt-to-Total-Asset of 0.14. The current LT-Debt-to-Total-Asset is 0.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current LT-Debt-to-Total-Asset is 0.14 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.